![](https://abc17news.b-cdn.net/abc17news.com/2021/06/E1m9z2fi-kmiz-biz-and-tech-375x225.png)
Pfizer to spend $11.6B on migraine treatment maker Biohaven
By TOM MURPHY AP Health Writer Pfizer is starting to put its COVID-19 cash influx to use by spending $11.6 billion to venture deeper into a new treatment area. The New York vaccine and cancer drug maker said Tuesday it will use cash on hand to buy the remaining portion of migraine treatment developer Biohaven
Continue Reading